Literature DB >> 27480083

A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report.

Silvia Grassilli1, Ervin Nika1, Elisabetta Lambertini2, Federica Brugnoli1, Roberta Piva2, Silvano Capitani1,3, Valeria Bertagnolo4.   

Abstract

PURPOSE: Reduced expression of miR-142-3p has been found to be associated with the development of various subtypes of myeloid leukemia, including acute promyelocytic leukemia (APL). In APL-derived cells, miR-142-3p expression can be restored by all-trans retinoic acid (ATRA), which induces the completion of their maturation program. Here, we aimed to assess whether PU.1, essential for ATRA-induced gene transcription, regulates the expression of miR-142-3p in APL-derived cells and, based on the established cooperation between PU.1 and Vav1 in modulating gene expression, to evaluate the role of Vav1 in restoring the expression of miR-142-3p.
METHODS: ATRA-induced increases in PU.1 and Vav1 expression in APL-derived NB4 cells were counteracted with specific siRNAs, and the expression of miR-142-3p was measured by quantitative real-time PCR (qRT-PCR). The recruitment of PU.1 and/or Vav1 to the regulatory region of miR-142 was assessed by quantitative chromatin immunoprecipitation (Q-ChIP). Synthetic inhibitors or mimics for miR-142-3p were used to assess whether this miRNA plays a role in regulating the expression of PU.1 and/or Vav1.
RESULTS: We found that the expression of miR-142-3p in differentiating APL-derived NB4 cells is dependent on PU.1, and that Vav1 is essential for the recruitment of this transcription factor to its cis-binding element on the miR-142 promoter. In addition, we found that in ATRA-treated NB4 cells miR-142-3p sustains agonist-induced increases in both PU.1 and Vav1.
CONCLUSIONS: Our results suggest the existence of a Vav1/PU.1/miR-142-3p network that supports ATRA-induced differentiation in APL-derived cells. Since selective regulation of miRNAs may play a role in the future treatment of hematopoietic malignancies, our results may provide a basis for the development of new therapeutic strategies to restore the expression of miR-142-3p.

Entities:  

Keywords:  ATRA; Acute promyelocytic leukemia; PU.1; Vav1; miR-142-3p

Mesh:

Substances:

Year:  2016        PMID: 27480083     DOI: 10.1007/s13402-016-0292-6

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  34 in total

Review 1.  Vav1 in differentiation of tumoral promyelocytes.

Authors:  Valeria Bertagnolo; Federica Brugnoli; Silvia Grassilli; Ervin Nika; Silvano Capitani
Journal:  Cell Signal       Date:  2011-11-28       Impact factor: 4.315

2.  Vav promotes differentiation of human tumoral myeloid precursors.

Authors:  Valeria Bertagnolo; Federica Brugnoli; Carlo Mischiati; Alessia Sereni; Alberto Bavelloni; Cinzia Carini; Silvano Capitani
Journal:  Exp Cell Res       Date:  2005-03-17       Impact factor: 3.905

Review 3.  The prognostic and functional role of microRNAs in acute myeloid leukemia.

Authors:  Guido Marcucci; Krzysztof Mrózek; Michael D Radmacher; Ramiro Garzon; Clara D Bloomfield
Journal:  Blood       Date:  2010-11-02       Impact factor: 22.113

Review 4.  PU.1: a crucial and versatile player in hematopoiesis and leukemia.

Authors:  Philippe Kastner; Susan Chan
Journal:  Int J Biochem Cell Biol       Date:  2007-02-04       Impact factor: 5.085

Review 5.  The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment.

Authors:  Francesco Lo-Coco; Emanuele Ammatuna
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2006

6.  miR-142-3p restricts cAMP production in CD4+CD25- T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA.

Authors:  Bo Huang; Jie Zhao; Zhang Lei; Shiqian Shen; Dong Li; Guan-Xin Shen; Gui-Mei Zhang; Zuo-Hua Feng
Journal:  EMBO Rep       Date:  2008-12-19       Impact factor: 8.807

Review 7.  Oncogenic microRNAs in the genesis of leukemia and lymphoma.

Authors:  Yanyan Pan; Mei Meng; Gaochuan Zhang; Hongyan Han; Quansheng Zhou
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  Combined characterization of microRNA and mRNA profiles delineates early differentiation pathways of CD133+ and CD34+ hematopoietic stem and progenitor cells.

Authors:  Ute Bissels; Stefan Wild; Stefan Tomiuk; Markus Hafner; Hartmut Scheel; Aleksandra Mihailovic; Yeong-Hoon Choi; Thomas Tuschl; Andreas Bosio
Journal:  Stem Cells       Date:  2011-05       Impact factor: 6.277

9.  Vav1 is a component of transcriptionally active complexes.

Authors:  Martin Houlard; Ramachandran Arudchandran; Fabienne Regnier-Ricard; Antonia Germani; Sylvie Gisselbrecht; Ulrich Blank; Juan Rivera; Nadine Varin-Blank
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

Review 10.  PU.1 and partners: regulation of haematopoietic stem cell fate in normal and malignant haematopoiesis.

Authors:  Pallavi Gupta; Gangenahalli U Gurudutta; Daman Saluja; Rajendra P Tripathi
Journal:  J Cell Mol Med       Date:  2009-04-06       Impact factor: 5.310

View more
  7 in total

1.  Vav1 Selectively Down-Regulates Akt2 through miR-29b in Certain Breast Tumors with Triple Negative Phenotype.

Authors:  Silvia Grassilli; Federica Brugnoli; Stefano Cairo; Nicoletta Bianchi; Jean-Gabriel Judde; Valeria Bertagnolo
Journal:  J Pers Med       Date:  2022-06-17

2.  Upregulation of miR-142-3p Improves Drug Sensitivity of Acute Myelogenous Leukemia through Reducing P-Glycoprotein and Repressing Autophagy by Targeting HMGB1.

Authors:  Yuan Zhang; Yufeng Liu; Xueju Xu
Journal:  Transl Oncol       Date:  2017-04-23       Impact factor: 4.243

3.  Transcriptional suppression of microRNA-27a contributes to laryngeal cancer differentiation via GSK-3β-involved Wnt/β-catenin pathway.

Authors:  Sheng Chen; Yuan-Yuan Sun; Zhao-Xiong Zhang; Yun-Hui Li; Zhen-Ming Xu; Wei-Neng Fu
Journal:  Oncotarget       Date:  2017-02-28

4.  The c-Raf modulator RRD-251 enhances nuclear c-Raf/GSK-3/VDR axis signaling and augments 1,25-dihydroxyvitamin D3-induced differentiation of HL-60 myeloblastic leukemia cells.

Authors:  Harrison T Supnick; Rodica P Bunaciu; Andrew Yen
Journal:  Oncotarget       Date:  2018-01-19

5.  Vav1 is necessary for PU.1 mediated upmodulation of miR-29b in acute myeloid leukaemia-derived cells.

Authors:  Federica Vezzali; Silvia Grassilli; Elisabetta Lambertini; Federica Brugnoli; Simone Patergnani; Ervin Nika; Roberta Piva; Paolo Pinton; Silvano Capitani; Valeria Bertagnolo
Journal:  J Cell Mol Med       Date:  2018-03-13       Impact factor: 5.310

6.  Vav1 downmodulates Akt in different breast cancer subtypes: a new promising chance to improve breast cancer outcome.

Authors:  Silvia Grassilli; Federica Brugnoli; Rossano Lattanzio; Marco Marchisio; Letizia Perracchio; Mauro Piantelli; Alberto Bavelloni; Silvano Capitani; Valeria Bertagnolo
Journal:  Mol Oncol       Date:  2018-05-16       Impact factor: 6.603

7.  Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.

Authors:  Valeria Bertagnolo; Silvia Grassilli; Stefano Volinia; Yasamin Al-Qassab; Federica Brugnoli; Federica Vezzali; Elisabetta Lambertini; Maria Palomba; Quirino Piubello; Enrico Orvieto; Cristina Natali; Roberta Piva; Carlo Maria Croce; Silvano Capitani
Journal:  Mol Carcinog       Date:  2019-01-16       Impact factor: 4.784

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.